QIAGEN N.V. (QGEN) Stock Fundamental Analysis
USA - NYSE:QGEN - NL0015002CX3 - Common Stock
45.94 USD
+0.2 (+0.44%)
45.94 USD
0 (0%)
Overall QGEN gets a fundamental rating of 6 out of 10. We evaluated QGEN against 56 industry peers in the Life Sciences Tools & Services industry. QGEN scores excellent points on both the profitability and health parts. This is a solid base for a good stock. QGEN is not valued too expensively and it also shows a decent growth rate. This makes QGEN very considerable for quality investing!
1. Profitability
1.1 Basic Checks
In the past year QGEN was profitable.
QGEN had a positive operating cash flow in the past year.
In the past 5 years QGEN has always been profitable.
In the past 5 years QGEN always reported a positive cash flow from operatings.
1.2 Ratios
QGEN has a better Return On Assets (6.41%) than 82.14% of its industry peers.
The Return On Equity of QGEN (10.65%) is better than 80.36% of its industry peers.
With an excellent Return On Invested Capital value of 8.66%, QGEN belongs to the best of the industry, outperforming 83.93% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for QGEN is significantly below the industry average of 15.41%.
The last Return On Invested Capital (8.66%) for QGEN is above the 3 year average (7.25%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.41% | ||
| ROE | 10.65% | ||
| ROIC | 8.66% |
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
1.3 Margins
QGEN's Profit Margin of 18.30% is amongst the best of the industry. QGEN outperforms 91.07% of its industry peers.
In the last couple of years the Profit Margin of QGEN has declined.
QGEN's Operating Margin of 26.86% is amongst the best of the industry. QGEN outperforms 94.64% of its industry peers.
In the last couple of years the Operating Margin of QGEN has grown nicely.
QGEN's Gross Margin of 64.18% is amongst the best of the industry. QGEN outperforms 85.71% of its industry peers.
QGEN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.86% | ||
| PM (TTM) | 18.3% | ||
| GM | 64.18% |
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so QGEN is still creating some value.
The number of shares outstanding for QGEN has been reduced compared to 1 year ago.
The number of shares outstanding for QGEN has been reduced compared to 5 years ago.
The debt/assets ratio for QGEN has been reduced compared to a year ago.
2.2 Solvency
QGEN has an Altman-Z score of 3.99. This indicates that QGEN is financially healthy and has little risk of bankruptcy at the moment.
QGEN's Altman-Z score of 3.99 is fine compared to the rest of the industry. QGEN outperforms 78.57% of its industry peers.
The Debt to FCF ratio of QGEN is 2.91, which is a good value as it means it would take QGEN, 2.91 years of fcf income to pay off all of its debts.
QGEN's Debt to FCF ratio of 2.91 is amongst the best of the industry. QGEN outperforms 80.36% of its industry peers.
QGEN has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.25, QGEN perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 2.91 | ||
| Altman-Z | 3.99 |
ROIC/WACC1.1
WACC7.84%
2.3 Liquidity
QGEN has a Current Ratio of 1.61. This is a normal value and indicates that QGEN is financially healthy and should not expect problems in meeting its short term obligations.
QGEN's Current ratio of 1.61 is on the low side compared to the rest of the industry. QGEN is outperformed by 69.64% of its industry peers.
A Quick Ratio of 1.35 indicates that QGEN should not have too much problems paying its short term obligations.
QGEN has a Quick ratio of 1.35. This is in the lower half of the industry: QGEN underperforms 69.64% of its industry peers.
The current and quick ratio evaluation for QGEN is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.61 | ||
| Quick Ratio | 1.35 |
3. Growth
3.1 Past
QGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.20%, which is quite good.
Measured over the past years, QGEN shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.40% on average per year.
The Revenue has been growing slightly by 5.15% in the past year.
Measured over the past years, QGEN shows a small growth in Revenue. The Revenue has been growing by 5.32% on average per year.
EPS 1Y (TTM)12.2%
EPS 3Y-6.66%
EPS 5Y8.4%
EPS Q2Q%6.06%
Revenue 1Y (TTM)5.15%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%7.49%
3.2 Future
QGEN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.02% yearly.
Based on estimates for the next years, QGEN will show a small growth in Revenue. The Revenue will grow by 7.38% on average per year.
EPS Next Y7.88%
EPS Next 2Y8.09%
EPS Next 3Y8.68%
EPS Next 5Y8.02%
Revenue Next Year5.25%
Revenue Next 2Y5.47%
Revenue Next 3Y5.89%
Revenue Next 5Y7.38%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 19.55, the valuation of QGEN can be described as rather expensive.
Based on the Price/Earnings ratio, QGEN is valued cheaply inside the industry as 85.71% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 27.38. QGEN is valued slightly cheaper when compared to this.
The Price/Forward Earnings ratio is 17.69, which indicates a rather expensive current valuation of QGEN.
Based on the Price/Forward Earnings ratio, QGEN is valued cheaper than 83.93% of the companies in the same industry.
QGEN is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.86, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.55 | ||
| Fwd PE | 17.69 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of QGEN indicates a rather cheap valuation: QGEN is cheaper than 89.29% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, QGEN is valued cheaper than 83.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.08 | ||
| EV/EBITDA | 13.89 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of QGEN may justify a higher PE ratio.
PEG (NY)2.48
PEG (5Y)2.33
EPS Next 2Y8.09%
EPS Next 3Y8.68%
5. Dividend
5.1 Amount
With a yearly dividend of 0.55%, QGEN is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 0.54, QGEN pays a better dividend. On top of this QGEN pays more dividend than 91.07% of the companies listed in the same industry.
With a Dividend Yield of 0.55, QGEN pays less dividend than the S&P500 average, which is at 2.38.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.55% |
5.2 History
QGEN does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y8.09%
EPS Next 3Y8.68%
45.94
+0.2 (+0.44%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners87.24%
Inst Owner Change-22.15%
Ins Owners0.44%
Ins Owner ChangeN/A
Market Cap9.96B
Analysts75
Price Target52.82 (14.98%)
Short Float %3.15%
Short Ratio4.57
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.55% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.7%
Min EPS beat(2)-2.4%
Max EPS beat(2)7.8%
EPS beat(4)2
Avg EPS beat(4)1.23%
Min EPS beat(4)-3.85%
Max EPS beat(4)7.8%
EPS beat(8)5
Avg EPS beat(8)1.51%
EPS beat(12)8
Avg EPS beat(12)3.69%
EPS beat(16)12
Avg EPS beat(16)5.44%
Revenue beat(2)1
Avg Revenue beat(2)0.66%
Min Revenue beat(2)-0.12%
Max Revenue beat(2)1.43%
Revenue beat(4)1
Avg Revenue beat(4)-0.16%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.43%
Revenue beat(8)1
Avg Revenue beat(8)-0.61%
Revenue beat(12)3
Avg Revenue beat(12)-0.41%
Revenue beat(16)7
Avg Revenue beat(16)0.85%
PT rev (1m)2.48%
PT rev (3m)4.48%
EPS NQ rev (1m)0.43%
EPS NQ rev (3m)0.96%
EPS NY rev (1m)0%
EPS NY rev (3m)0.53%
Revenue NQ rev (1m)0.17%
Revenue NQ rev (3m)2%
Revenue NY rev (1m)0.14%
Revenue NY rev (3m)1.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.55 | ||
| Fwd PE | 17.69 | ||
| P/S | 4.88 | ||
| P/FCF | 20.08 | ||
| P/OCF | 14.76 | ||
| P/B | 2.84 | ||
| P/tB | 15.58 | ||
| EV/EBITDA | 13.89 |
EPS(TTM)2.35
EY5.12%
EPS(NY)2.6
Fwd EY5.65%
FCF(TTM)2.29
FCFY4.98%
OCF(TTM)3.11
OCFY6.78%
SpS9.41
BVpS16.17
TBVpS2.95
PEG (NY)2.48
PEG (5Y)2.33
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.41% | ||
| ROE | 10.65% | ||
| ROCE | 11.67% | ||
| ROIC | 8.66% | ||
| ROICexc | 10.87% | ||
| ROICexgc | 46.44% | ||
| OM | 26.86% | ||
| PM (TTM) | 18.3% | ||
| GM | 64.18% | ||
| FCFM | 24.31% |
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
ROICexc(3y)9.42%
ROICexc(5y)10.13%
ROICexgc(3y)34.6%
ROICexgc(5y)42.77%
ROCE(3y)9.77%
ROCE(5y)10.73%
ROICexcg growth 3Y-31.24%
ROICexcg growth 5Y-2.41%
ROICexc growth 3Y-13.09%
ROICexc growth 5Y6.48%
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
F-Score8
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 2.91 | ||
| Debt/EBITDA | 1.2 | ||
| Cap/Depr | 94.78% | ||
| Cap/Sales | 8.78% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 91.61% | ||
| Profit Quality | 132.83% | ||
| Current Ratio | 1.61 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z | 3.99 |
F-Score8
WACC7.84%
ROIC/WACC1.1
Cap/Depr(3y)78.4%
Cap/Depr(5y)95.94%
Cap/Sales(3y)7.97%
Cap/Sales(5y)9.87%
Profit Quality(3y)273.85%
Profit Quality(5y)189.74%
High Growth Momentum
Growth
EPS 1Y (TTM)12.2%
EPS 3Y-6.66%
EPS 5Y8.4%
EPS Q2Q%6.06%
EPS Next Y7.88%
EPS Next 2Y8.09%
EPS Next 3Y8.68%
EPS Next 5Y8.02%
Revenue 1Y (TTM)5.15%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%7.49%
Revenue Next Year5.25%
Revenue Next 2Y5.47%
Revenue Next 3Y5.89%
Revenue Next 5Y7.38%
EBIT growth 1Y21.82%
EBIT growth 3Y-9.05%
EBIT growth 5Y9.63%
EBIT Next Year57.21%
EBIT Next 3Y22.62%
EBIT Next 5Y14.77%
FCF growth 1Y31.74%
FCF growth 3Y5.12%
FCF growth 5Y55.1%
OCF growth 1Y29.99%
OCF growth 3Y1.77%
OCF growth 5Y15.28%